862073-77-6|Herkinorin|Herkinorin, mu opioid agonist|-范德生物科技公司

Herkinorin

NMR下载 COA and HPLC MSDS下载
names：
Herkinorin, mu opioid agonist
CAS号：
862073-77-6
MDL Number：
MF(分子式)： C28H30O8 MW(分子量)： 494.54
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

Herkinorin 是一种有效且选择性的 μ阿片受体激动剂，Ki 为 45 nM。Herkinorin 被广泛用于疼痛研究

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Herkinorin(862073-77-6)；μ阿片受体激动剂；非内化μ阿片受体激动剂；Non-internalising μ opioid agonist
英文别名	Herkinorin, mu opioid agonist(862073-77-6)；BF3DNCA methyl ester；Herkinorin.
CAS号	862073-77-6
SMILES	O=C(C(CC(OC(C1=CC=CC=C1)=O)C(C23)=O)C2(C)CCC(C3(C)CC(C4=COC=C4)O5)C5=O)OC
Inchi	InChI=1S/C28H30O8/c1-27-11-9-18-26(32)36-21(17-10-12-34-15-17)14-28(18,2)23(27)22(29)20(13-19(27)25(31)33-3)35-24(30)16-7-5-4-6-8-16/h4-8,10,12,15,18-21,23H,9,11,13-14H2,1-3H3
InchiKey	PYDQMXRFUVDCHC-UHFFFAOYSA-N
分子式 Formula	C28H30O8
分子量 Molecular Weight	494.54
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Herkinorin(CAS:862073-77-6):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Herkinorin is an opioid analgesic that is an analogue of the natural product Salvinorin A. Unlike Salvinorin A which is a selective κ-opioid agonist with no significant μ-opioid receptor affinity, herkinorin is a μ-opioid agonist with more than 100x higher μ-opioid affinity and 50x lower κ-opioid affinity compared to Salvinorin A. Herkinorin is a semi-synthetic compound, made from Salvinorin B, which is most conveniently made from Salvinorin A by deacetylation, as while both Salvinorin A and Salvinorin B are found in the plant Salvia divinorum, Salvinorin A is present in larger quantities.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Butelman ER, Rus S, Simpson DS, Wolf A, Prisinzano TE, Kreek MJ. The effects of herkinorin, the first mu-selective ligand from a salvinorin A-derived scaffold, in a neuroendocrine biomarker assay in nonhuman primates. J Pharmacol Exp Ther. 2008 Oct;327(1):154-60. doi: 10.1124/jpet.108.140079. Epub 2008 Jul [1] PubMed PMID: 18593955; PubMed Central PMCID: PMC2614932.

[2]Ji F, Wang Z, Ma N, Riley J, Armstead WM, Liu R. Herkinorin dilates cerebral vessels via kappa opioid receptor and cyclic adenosine monophosphate (cAMP) in a piglet model. Brain Res. 2013 Jan 15;1490:95-100. doi: 10.1016/j.brainres.2012.10.024. Epub 2012 Oct 24. PubMed PMID: 23103502; PubMed Central PMCID: PMC3529796.

[3] Lamb K, Tidgewell K, Simpson DS, Bohn LM, Prisinzano TE. Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend. 2012 Mar 1;121(3):181-8. doi: 10.1016/j.drugalcdep.2011.10.026. Epub 2011 Nov 26. PubMed PMID: 22119134; PubMed Central PMCID: PMC3288203.

[4] Xu H, Partilla JS, Wang X, Rutherford JM, Tidgewell K, Prisinzano TE, Bohn LM, Rothman RB. A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence. Synapse. 2007 Mar;61(3):166-75. PubMed PMID: 17152090.

[5] Rowan MP, Bierbower SM, Eskander MA, Szteyn K, Por ED, Gomez R, Veldhuis N, Bunnett NW, Jeske NA. Activation of mu opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) via β-arrestin-2-mediated cross-talk. PLoS One. 2014 Apr 2;9(4):e93688. doi: 10.1371/journal.pone.0093688. eCollection 2014. PubMed PMID: 24695785; PubMed Central PMCID: PMC3973553.

6: Tidgewell K, Groer CE, Harding WW, Lozama A, Schmidt M, Marquam A, Hiemstra J, Partilla JS, Dersch CM, Rothman RB, Bohn LM, Prisinzano TE. Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31. doi: 10.1021/jm701162g. Epub 2008 Apr 2. PubMed PMID: 18380425; PubMed Central PMCID: PMC2494883.7: Bartuzi D, Kaczor AA, Matosiuk D. Activation and Allosteric Modulation of Human μ Opioid Receptor in Molecular Dynamics. J Chem Inf Model. 2015 Nov 23;55(11):2421-34. doi: 10.1021/acs.jcim.5b00280. Epub 2015 Nov 11. PubMed PMID: 26517559.8: Prisinzano TE. Neoclerodanes as atypical opioid receptor ligands. J Med Chem. 2013 May 9;56(9):3435-43. doi: 10.1021/jm400388u. Epub 2013 Apr 18. Review. PubMed PMID: 23548164; PubMed Central PMCID: PMC3671615.9: Sally EJ, Xu H, Dersch CM, Hsin LW, Chang LT, Prisinzano TE, Simpson DS, Giuvelis D, Rice KC, Jacobson AE, Cheng K, Bilsky EJ, Rothman RB. Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor. Synapse. 2010 Apr;64(4):280-8. doi: 10.1002/syn.20723. PubMed PMID: 19953652; PubMed Central PMCID: PMC2821452.10: Marmolejo-Valencia AF, Martínez-Mayorga K. Allosteric modulation model of the mu opioid receptor by herkinorin, a potent not alkaloidal agonist. J Comput Aided Mol Des. 2017 May;31(5):467-482. doi: 10.1007/s10822-017-0016-7. Epub 2017 Mar 31. PubMed PMID: 28364251.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开